Back to mobile site

More on MIST

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (-83.3% Growth)
- Ratings (8.9 Score)

Upcoming Events

- Earnings (11/17/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Milestone Pharmaceuticals Inc. (NQ:MIST)
Delayed: 0.77 +0.01 (1.32%)
Prev. Close $0.76  
Open$0.78 
52 Wk High$ 
52 Wk Low$ 
Day High$0.78 
Day Low$0.74 
P/E N/A  
EPS$ 
Volume209,226 

Friends, Peers and Foes (?): ATR, ACOG, CBAY, ONCT, ALNY (more...)

Oct 9, 2026 08:00 AM Milestone Pharmaceuticals enrolls first European patient in AFib trial
Oct 9, 2026 08:00 AM Milestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical Trial
Sep 24, 2026 08:01 AM Milestone Pharmaceuticals enrolls first Canadian patient in AFib trial
Sep 24, 2026 08:00 AM Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR
Sep 4, 2026 06:46 AM H.C. Wainwright Reiterates Buy Rating on Milestone Pharmaceuticals (MIST)
Aug 27, 2026 08:01 AM Milestone study finds PSVT impacts patient life between episodes
Aug 27, 2026 08:00 AM Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients’ Daily Lives and Quality of Life Between Episodes
Aug 21, 2026 08:00 AM Milestone Pharmaceuticals starts Phase 3 AFib-RVR trial for etripamil
Aug 21, 2026 08:00 AM Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)
Aug 20, 2026 06:08 AM Cantor Fitzgerald Starts Milestone Pharmaceuticals (MIST) at Overweight
View All Articles

Entities mentioned with MIST

View All Entities